Sveriges mest populära poddar

Blood Podcast

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

309 avsnitt • Längd: 20 min • Veckovis: Torsdag

Om podden

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

The podcast Blood Podcast is created by American Society of Hematology. The podcast and the artwork on this page are embedded on this page using the public podcast feed (RSS).

Avsnitt

Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL

3 april 2025 | 15 min
Read More

Blood Bonus Episode: What is a Blood group?

31 mars 2025 | 15 min
Read More

Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait

27 mars 2025 | 19 min
Read More

Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis

20 mars 2025 | 19 min
Read More

Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL

13 mars 2025 | 21 min
Read More

Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk

6 mars 2025 | 18 min
Read More

Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal antibodies

27 februari 2025 | 19 min
Read More

Review Series on a Quarter Century of TKIs in CML

27 februari 2025 | 33 min
Read More

A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes

21 februari 2025 | 19 min
Read More

Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

13 februari 2025 | 23 min
Read More

Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor

13 februari 2025 | 32 min
Read More

Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor

6 februari 2025 | 19 min
Read More

First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia

30 januari 2025 | 21 min
Read More

Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex

23 januari 2025 | 19 min
Read More

Review Series on Globin Disorders

23 januari 2025 | 23 min
Read More

Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma

16 januari 2025 | 22 min
Read More

Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk

9 januari 2025 | 17 min
Read More

Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

2 januari 2025 | 20 min
Read More

Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

26 december 2024 | 19 min
Read More

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

19 december 2024 | 20 min
Read More
00:00 -00:00